Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
Official title: A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV
Funded at Emory University · NIH-11590657 · Data updated 2026-11-12
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 19, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $317,520 |
| NIH project number | 3U01AI186860-02S1 |
| Project ID | NIH-11590657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults in areas with dengue transmission who are eligible for dengue vaccination and consent to participate in a vaccine-immune study.
✕Less likely to help
Individuals who do not respond to vaccines or those not receiving the heterologous boost may see limited or no personal benefit.
What this research studies
This study will enroll participants to receive a prime-boost vaccination strategy using two dengue vaccines. Researchers will measure immune responses over time to see if the boost expands memory B cells and produces broad, durable protection against the four dengue serotypes. The trial is designed as a randomized, open-label phase 2b study to explore safety and immune outcomes in adults at risk for dengue exposure. If successful, results could inform future vaccination strategies to reduce dengue disease burden in endemic areas.
Why it matters
Potential benefit: If successful, the approach could lead to a more durable and broadly protective dengue vaccine strategy for people in dengue-endemic regions.
How similar studies have gone: Prior dengue vaccine studies have shown variable protection and raised questions about enhancing broad immunity; this trial tests a novel boost strategy to improve durability and breadth.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Collins, Matthew — Emory University
- Study coordinator: Collins, Matthew
Related research
Other NIH-funded projects on the same topics.
-
Dengue vaccine study using two vaccines together to strengthen and broaden immunity
A Phase 2b trial tests whether giving TAK-003 followed by Butantan-DV boosts broad, durable antibodies against dengue in adults who have been vaccinated before.
-
Movement-Enhanced Walking Training to Improve Balance After Stroke
A specialized treadmill training using a cable-driven device, called Movement Amplification Environment (MAE), helps people with chronic stroke improve walking balance by enhancing their own movement awareness.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.